NPM1 and acute myeloid leukemia: The KOMET-001 multicenter, open-label, multicohort phase I/II clinical trial evaluated Ziftomenib in adult R/R AML patients; the study was subdivided into two phases: a phase Ia (dose–response), in which the patients received Ziftomenib (from 50 to 1000 mg) orally once daily in 28-day cycles; and a phase Ib, in which patients with KMT2A rearrangements or NPM1 mutations were randomly assigned to two parallel dose cohorts (200 and 600 mg Ziftomenib) [123].